Alex Sargent, Director of Process Development at Charles River in our Cell and Gene Therapy department, joins me to discuss the work he and his partner put into developing an algorithm to make his job faster and easier. How can you train a computer to accurately sift through the mountains of data generated in drug development? Listen now to find out!

There have been many articles recently about cellular agriculture, or lab-grown meat products. But what happens when a company takes a practical approach to this science fiction concept? Joining me are Charles River's Steven Miklasz from our Biologics Testing Solutions team; and Ramsey Foty, Scientific Director for Fork & Good, a cultivated meat company, to discuss how the sausage is made!

This month I am joined by Benjamin Oakes, scientist, entrepreneur, and co-founder of Scribe Therapeutics. He studied at UC Berkeley, working in the Doudna Lab and Savage Lab during the earliest days of CRISPR. We discuss his personal vision for the future of CRISPR, encouraging advances in the field, and the first ever drug approval for a CRISPR based therapy. 

Norm Wainwright and Foster Jordan have been immersed in the field of limulus amebocyte lysate (LAL) testing for decades, and have seen the progress and refinement of this crucial safety test. With the 20th anniversary of Charles River's Endosafe Cartridge and the recent introduction of recombinant alternatives, we look back at the past and future of endotoxin testing.

I am joined by four experts in their field to discuss what will be hot in rare diseases, drug discovery, artificial intelligence, and animal models in 2024. 

Molly Dupre, a lab assistant at Charles River's Reno site, was recently diagnosed with Niemann-Pick Type B/ Acid Sphingomyelinase Deficiency. After years of waiting, doctor's visits, and tests, she could finally put a name to the condition that flared up after the birth of her son. But what came next? She joins me to tell her story.

Senior Principal Scientific Advisor Stan Spence joins me to discuss off-target liability: what happens when a drug misses its target? What are the risks to the patient if the off-target effects aren't caught early? Has there ever been an example of an off-target effect being beneficial to the patient? Find out here!

Rachel Kiserow and Susan Desmond have joined us year after year as part of Eureka's Breast Cancer Roundtable. This year, they wanted to share what happens after - after the treatments, after remission - life after cancer.

For this episode, I am joined by Charles River's Doug Botkin and Pure Microbiology's Abby Roth to discuss the 2012 NECC meningitis outbreak. Doug and Abby bring their background in microbiology to explain how it happened, and how we can prevent such tragedies in the future. 

Charles River experts Justin Bryans and Elizabeth Anderson join me for a spirited discussion of where we are now in oncology research. Could we ever see a world without cancer?